Publications by category
Journal articles
Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, Hatswell AJ, Melendez-Torres GJ, Crathorne L (2020). Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: an Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
Pharmacoeconomics,
38(12), 1309-1318.
Abstract:
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: an Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
The UK National Institute for Health and Care Excellence (NICE) considered evidence for voretigene neparvovec (VN; Luxturna®) for the treatment of RPE65-mediated inherited retinal dystrophies (IRD) within its highly specialised technology programme. This paper summarises the evidence provided by the company; the appraisal of the evidence by the Peninsula Technology Appraisal Group, who were commissioned to act as the independent evidence review group (ERG); and the development of the NICE guidance by the appraisal committee. The evidence presented by the company highlighted the significant lifelong burden of IRD for patients and carers. Evidence to support the effectiveness of VN was lacking, but the available evidence showed a modest, sustained improvement across a variety of vision-related outcomes. While patients would remain visually impaired, the committee considered that VN would prevent further deterioration in vision. The modelling approach used by the company had a number of limitations and relied heavily upon a large volume of clinical expert input to produce cost-effectiveness estimates with large uncertainty around long-term effectiveness. The ERG's main concerns revolved around these long-term outcomes and the plausibility of utility values. The NICE committee were convinced that the clinical benefits of VN were important and an appropriate use of national health service resources within a specialised service. The committee concluded that a high unmet need existed in patients with RPE65-mediated IRD and that VN represents a step change in the management of this condition.
Abstract.
Author URL.
Varley-Campbell J, Mujica Mota R, Coelho H, Ocean N, Barnish M, Packman D, Dodman S, Cooper C, Snowsill TM, Kay T, et al (2019). Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation.
Health Technology Assessment,
23(13).
Full text.
Nicol‑Harper A, Dooley C, Packman D, Mueller M, Bijak J, Hodgson D, Townley S, Ezard T (2018). Inferring transient dynamics of human populations from matrix non-normality.
Population Ecology Full text.
Guiver C, Packman D, Townley S (2017). A necessary condition for dispersal driven growth of populations with discrete patch dynamics.
J Theor Biol,
424, 11-25.
Abstract:
A necessary condition for dispersal driven growth of populations with discrete patch dynamics.
We revisit the question of when can dispersal-induced coupling between discrete sink populations cause overall population growth? Such a phenomenon is called dispersal driven growth and provides a simple explanation of how dispersal can allow populations to persist across discrete, spatially heterogeneous, environments even when individual patches are adverse or unfavourable. For two classes of mathematical models, one linear and one non-linear, we provide necessary conditions for dispersal driven growth in terms of the non-existence of a common linear Lyapunov function, which we describe. Our approach draws heavily upon the underlying positive dynamical systems structure. Our results apply to both discrete- and continuous-time models. The theory is illustrated with examples and both biological and mathematical conclusions are drawn.
Abstract.
Author URL.
Reports
Barnish M, Cummins E, Coelho H, Johnston R, Packman D, Shaw N, Haigh R, Crathorne L, Melendez-Torres GJ (2020). Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]: a Single Technology Appraisal. NICE.
Bello S, Griffin E, Farmer C, Nikram E, Robinson S, Packman D, Salmon A, Cossburn M, Melendez-Torres GJ, Crathorne L, et al (2019). Fremanezumab for preventing migraine: a Single Technology Appraisal. NICE.
Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, Bello S, Dodman S, Rezaei Hemami M, Churchill A, et al (2019). Voretigene neparvovec for inherited retinal dystrophies (RPE65 mutations) [ID1054]: a Highly Specialised Technology Evaluation. NICE.
Barnish M, Varley-Campbell J, Coelho H, Dodman S, Snowsill T, Mujica-Mota R, Packman D, Ocean N, Kay T, Liversedge N, et al (2018). Biomarker tests to help diagnose preterm labour in symptomatic women with intact membranes: a systematic review.
Varley-Campbell J, Mujica-Mota R, Coelho H, Ocean N, Barnish M, Packman D, Dodman S, Cooper C, Snowsill T, Kay T, et al (2018). Biomarker tests to help diagnose preterm labour in women with intact membranes. NICE.
Griffin E, Barnish M, Packman D, Coelho H, Matthews J, Dodman S, Robinson S, Dangoor A, Dorey N, Hoyle M, et al (2018). Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib: a Single Technology Appraisal. NICE.
Griffin E, Farmer C, Packman D, Nikram E, Matthews J, Barnish M, Briscoe S, Dorey N, Dangoor A, Mujica Mota R, et al (2018). Pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer [ID1173]: a Single Technology Appraisal. NICE.
Publications by year
2020
Barnish M, Cummins E, Coelho H, Johnston R, Packman D, Shaw N, Haigh R, Crathorne L, Melendez-Torres GJ (2020). Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]: a Single Technology Appraisal. NICE.
Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, Hatswell AJ, Melendez-Torres GJ, Crathorne L (2020). Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: an Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
Pharmacoeconomics,
38(12), 1309-1318.
Abstract:
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: an Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
The UK National Institute for Health and Care Excellence (NICE) considered evidence for voretigene neparvovec (VN; Luxturna®) for the treatment of RPE65-mediated inherited retinal dystrophies (IRD) within its highly specialised technology programme. This paper summarises the evidence provided by the company; the appraisal of the evidence by the Peninsula Technology Appraisal Group, who were commissioned to act as the independent evidence review group (ERG); and the development of the NICE guidance by the appraisal committee. The evidence presented by the company highlighted the significant lifelong burden of IRD for patients and carers. Evidence to support the effectiveness of VN was lacking, but the available evidence showed a modest, sustained improvement across a variety of vision-related outcomes. While patients would remain visually impaired, the committee considered that VN would prevent further deterioration in vision. The modelling approach used by the company had a number of limitations and relied heavily upon a large volume of clinical expert input to produce cost-effectiveness estimates with large uncertainty around long-term effectiveness. The ERG's main concerns revolved around these long-term outcomes and the plausibility of utility values. The NICE committee were convinced that the clinical benefits of VN were important and an appropriate use of national health service resources within a specialised service. The committee concluded that a high unmet need existed in patients with RPE65-mediated IRD and that VN represents a step change in the management of this condition.
Abstract.
Author URL.
2019
Bello S, Griffin E, Farmer C, Nikram E, Robinson S, Packman D, Salmon A, Cossburn M, Melendez-Torres GJ, Crathorne L, et al (2019). Fremanezumab for preventing migraine: a Single Technology Appraisal. NICE.
Varley-Campbell J, Mujica Mota R, Coelho H, Ocean N, Barnish M, Packman D, Dodman S, Cooper C, Snowsill TM, Kay T, et al (2019). Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation.
Health Technology Assessment,
23(13).
Full text.
Farmer C, Bullement A, Packman D, Long L, Robinson S, Nikram E, Bello S, Dodman S, Rezaei Hemami M, Churchill A, et al (2019). Voretigene neparvovec for inherited retinal dystrophies (RPE65 mutations) [ID1054]: a Highly Specialised Technology Evaluation. NICE.
2018
Barnish M, Varley-Campbell J, Coelho H, Dodman S, Snowsill T, Mujica-Mota R, Packman D, Ocean N, Kay T, Liversedge N, et al (2018). Biomarker tests to help diagnose preterm labour in symptomatic women with intact membranes: a systematic review.
Varley-Campbell J, Mujica-Mota R, Coelho H, Ocean N, Barnish M, Packman D, Dodman S, Cooper C, Snowsill T, Kay T, et al (2018). Biomarker tests to help diagnose preterm labour in women with intact membranes. NICE.
Griffin E, Barnish M, Packman D, Coelho H, Matthews J, Dodman S, Robinson S, Dangoor A, Dorey N, Hoyle M, et al (2018). Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib: a Single Technology Appraisal. NICE.
Nicol‑Harper A, Dooley C, Packman D, Mueller M, Bijak J, Hodgson D, Townley S, Ezard T (2018). Inferring transient dynamics of human populations from matrix non-normality.
Population Ecology Full text.
Griffin E, Farmer C, Packman D, Nikram E, Matthews J, Barnish M, Briscoe S, Dorey N, Dangoor A, Mujica Mota R, et al (2018). Pembrolizumab with pemetrexed and platinum chemotherapy for untreated metastatic non-squamous non-small-cell lung cancer [ID1173]: a Single Technology Appraisal. NICE.
2017
Guiver C, Packman D, Townley S (2017). A necessary condition for dispersal driven growth of populations with discrete patch dynamics.
J Theor Biol,
424, 11-25.
Abstract:
A necessary condition for dispersal driven growth of populations with discrete patch dynamics.
We revisit the question of when can dispersal-induced coupling between discrete sink populations cause overall population growth? Such a phenomenon is called dispersal driven growth and provides a simple explanation of how dispersal can allow populations to persist across discrete, spatially heterogeneous, environments even when individual patches are adverse or unfavourable. For two classes of mathematical models, one linear and one non-linear, we provide necessary conditions for dispersal driven growth in terms of the non-existence of a common linear Lyapunov function, which we describe. Our approach draws heavily upon the underlying positive dynamical systems structure. Our results apply to both discrete- and continuous-time models. The theory is illustrated with examples and both biological and mathematical conclusions are drawn.
Abstract.
Author URL.
